The field of immunobiology has learned a great amount about how T cells function in the context of infections, cancer, and autoimmune responses using animal models. Yet, one area that has been difficult to study has been the modulation of endogenous T cells in peripheral tissues. One reason for this is that mice have a robust system of central tolerance established in the thymus that results in the "pruning" of the naïve T cell repertoire by eliminating or tolerizing CD8 and CD4 T cells with T cell receptors (TCRs) that recognize self-antigens [1] [2] [3] [4] [5] . These processes are crucial for maintaining tolerance but present a major engineering challenge for investigators interested in studying peripheral tolerance or in expressing inducible neoantigens from genome-encoded loci.
There have been several previous attempts to develop animal models that allow one to induce neoantigens in peripheral cells in a manner that bypasses central tolerance.
These include efforts to suppress the transcription/translation of a downstream neoantigen using genetic elements such as lox-STOP-lox (LSL) elements or tetinducible promoters [6] [7] [8] [9] [10] [11] . In the OFF state (pre-induction), these greatly reduce neoantigen expression, often to levels that are below the limit of detection by conventional methods. Yet, these methods often do not abrogate protein production completely, and there is a residual low level of "leaky" expression that, in the thymus or periphery, is sufficient to generate central or peripheral tolerance 7 . As a result, it has been difficult to generate mice with inducible genes that are lethal (i.e., LSL or tetinducible Diphtheria toxin), as these mice can have phenotypes from their leaky expression in sensitive tissues 12, 13 .
Central tolerance generally manifests as an incomplete or absent antigen-specific endogenous T cell response after infection with an antigen-expressing virus/bacteria or challenge with an antigen-expressing tumor cell line 7 . Alternatively, central tolerance occurs after crossing neoantigen-inducible mice to transgenic (Tg) mice that express
TCRs specific for the neoantigen 14, 15 . Here, central tolerance can take on many forms including outright deletion of neoantigen-specific T cells, marked-downregulation of TCR avidity, and the increased development of natural regulatory T cells (Tregs) [7] [8] [9] [10] [11] 16 .
Transfer of TCR Tg CD8 or CD4 T cells into inducible neoantigen mice has also been used to bypass central tolerance, but this can result in the activation and even tolerance of the transferred cells prior to antigen induction 7, 11 . This has required groups to provide inflammatory signals or infections coupled to antigen delivery to break antigenspecific tolerance, thus resulting in T cells attacking antigen-expressing self-tissues [17] [18] [19] , which can perturb the goal of studying how natural tolerance develops or is broken in peripheral tissues.
There is a clear need in the field to develop technology that allows for tight control over inducible expression of the neoantigens from germline encoded loci. To this end, we engineered the iNversion INducible Joined neoAntigen (NINJA) mouse to be compatible with Cre-inducible genetically-engineered mouse models of cancer like the "KP" model (Kras LSL-G12D;p53 flox/flox, 20 ). The NINJA allele consists of two modules.
The first one is a "neoantigen" module that uses DNA inversion to permanently induce neoantigen expression. DNA inversion is regulated by Flippase (FLPo) 21, 22 , which is encoded by a second "regulatory" module. In the regulatory module, FLPo is regulated at three levels requiring Cre-recombinase mediated recombination to "poise" the module, followed by doxycycline (D) and tamoxifen (T) to induce FLPo expression and activity, respectively.
Results
Design of the spliced neoantigen module. To generate a module encoding a neoantigen that would not have leaky expression in the OFF state, we reasoned that the DNA sequences encoding the full-length neoantigen should not exist within the genome prior to induction. Thus, we conceived of a gene in which the neoantigen-encoding DNA sequences were split across three exons, and the second exon was inverted relative to the first so that the gene could not transcribe/translate the full-length peptide antigen in the OFF state (Fig 1A) . Induction would be triggered by inversion of the second exon, which we determined would be achieved using FLPo and "non-compatible" FRT sites 21, 22 .
First, we identified neoantigens that had immunological tools for their analysis (i.e., MHC class I and class II tetramers, TCR Tg mice, etc.) and had sequences that could be engineered to contain in-frame splice donor and acceptor sites (Fig S1A) . Thus, we GP33-41 and GP66-77 are recognized by P14 and SMARTA CD8 and CD4 TCR Tg mice, respectively. In silico, we inserted RNA splice sites into the DNA and created two introns (Fig S1B) . We also inverted the sequences encoding exon 2, so that in the OFF state, the construct would splice directly from exons 1 to 3. To allow for induction of neoantigens in response to the recombinase FLPo, we inserted non-compatible FRT sites (F3 and FRT Wt; 22 ) to flank the inverted exon 2 sequence so that exposure to active FLPo would cause a permanent inversion of exon 2 (Fig S1C,  23 ).
Over the course of 7 iterative versions of the neoantigen module (NM.1-NM.7) (Fig   S2A) , we refined the design to ensure that the constructs had high fidelity before and after FLPo-mediated recombination at the DNA, RNA and protein levels (Fig S2, S3 , and data not shown). We also modified the construct so that inducible neoantigen was incorporated into the coding sequence of GFP in such a way that the non-fluorescent Nterminal portion of GFP was produced when the neoantigen module was OFF (before recombination) and full-length fluorescent GFP containing the neoantigens was produced when the module was ON (after recombination; Figs 1A and S3). Finally, we confirmed that the construct was unable to produce a cross-tolerizing GP33-43 peptide when the neoantigen module was in the OFF state (Fig S4) .
Validating the final neoantigen module construct. To test the final neoantigen module construct (NM.7) for functionality, we transfected 293T cells with the construct in the presence or absence of a plasmid encoding FLPo. After 72 hours, flow cytometric (FACS) analysis of the transfected cells showed robust GFP fluorescence in 293T cells transfected with the neoantigen module and FLPo, but no detectable fluorescence when FLPo was not co-transfected (Fig 1B) . This corresponded with a change in the size of the GFP protein from 27 kDa to 32 kDa (Fig S2C) . We also isolated the DNA from 293T cells after co-transfection with FLPo and confirmed that FLPo had faithfully recombined the neoantigen module by PCR and DNA sequencing (data not shown).
Next, we assessed the ability of the constructs to elicit responses by GP33-specific CD8 T cells. For this, we transiently transfected a dendritic cell line (DC2.4) with either GFP (negative control),the NM.7 construct or the NM.7 construct + FlpO. We cultured the transfected DC2.4 cells for 4 days alone or with cell-trace violet (CTV)-labeled CD8
T cells from GP33-43-specific P14 TCR Tg. In this assay, if P14 CD8 T cells recognize GP33-43 presented by DC2.4 cells, they become activated (dilute CTV and increase CD44 expression) and kill the adherent DC2.4 cells (leading to loss of crystal violet staining). In the GFP control (not shown) and NM.7 transduced wells, the P14 T cells remained naïve and the DC2.4 cells formed a confluent monolayer (Fig 1D) . By contrast, when DC2.4 cells were transfected with NM.7+FLPo, P14 T cells were activated and proliferated (Fig 1E) and killed the DC2.4 cells (Fig 1D) . Together, these data demonstrate that the NM.7 neoantigen module is non-immunogenic in the OFF state and immunogenic in the ON state after FLPo recombination.
Design of the regulatory module. We designed the regulatory module to contain a
Cre-inducible FLPo that is fused to amino acids 251-596 of the human estrogen receptor (ER) (FLPoER) and is expressed under the doxycycline-inducible pTRE-tight promoter (Fig 1A and S5) . Similar to the neoantigen module, in the regulatory module the DNA encoding the FLPoER sequence has been spliced and split into two exons in opposite orientations and requires Cre-recombinase-mediated inversion to become able to produce a functional protein (Fig 1A) . After Cre, the regulatory module is placed in the "poised" state, and subsequent FLPo activity requires D/T treatment. For this to happen, cells must also express the reverse tetracycline transactivator (rtTA), adding an extra potential layer of specificity (i.e., tissue-specific promoters expressing rtTA).
Assembly and testing of NINJA targeting construct. We inserted the regulatory and neoantigen modules into a Rosa26 targeting construct such that they were oriented in opposite directions (Fig 1A and S6) . This was done to avoid transcriptional interference in the regulatory module from the endogenous Rosa26 locus promoter. To minimize the impact of the CAG promoter (in the neoantigen module) on the pTRE promoter in the regulatory module, we inserted the 2x chicken gamma globulin (CGG) insulator between the regulatory and neoantigen modules. This construct was assembled in a Rosa26 targeting vector and will henceforth be referred to as the NINJA targeting construct (NINJA TC).
We next tested the NINJA TC in 293T cells. In the absence of Cre the neoantigen module remained OFF (GFP-), even when the cells were treated with D/T. By contrast, when cells were co-transfected with the full construct and Cre and rtTA, it was possible to turn on the neoantigen module (GFP+) with D/T treatment (Fig 1F) . These data confirm that the targeting construct functions as designed and induces neoantigens after Cre, doxycycline, and tamoxifen treatment.
Generating a NINJA-containing lung adenocarcinoma cell line. To test the functionality and fidelity of the components of the regulatory and neoantigen modules in the context of the Rosa26 locus, we used a murine KP lung cancer cell line to generate a knock-in cell line containing the NINJA targeting construct (KP-C4) (Fig 2A) . Proper targeting of the NINJA construct to the Rosa26 locus was verified by PCR (data not shown). We then transduced our KP-C4 cells with an rtTA-encoding retrovirus (KP-C4A3) and infected them with a recombinant Cre-expressing adenoviral vector (Ad-CRE) to cause a recombination in the regulatory module and place it permanently in the poised state (KP-C4A3D6) (Fig 2A) . We verified that the neoantigen module in the KP- (Fig 2B) .
To test immunogenicity, we sorted a pure GFP+ population of neoantigen expressing (ON) KP-C4A3D6 cells and compared these cells in vivo with KP-C4A3D6 that had never been exposed to D/T (OFF, Fig 2B) . We implanted the ON and OFF (Fig 2C) . Infiltration of neoantigen-specific P14 CD8 T cells into neoantigen-expressing tumors was confirmed by FACS (Fig 2D) and we also noted that the infiltrating T cells had a PD-1 hi phenotype, consistent with local cognate antigen exposure (Fig 2E and data not shown) .
One of the unique advantages of the NINJA system is the ability to induce the (Fig 2G) . Together, these data confirmed that NINJA is a system for tight regulation and induction of neoantigen expression.
Baseline "leaky" neoantigen expression not detected in NINJA mice. Having successfully generated and tested the NINJA targeting construct, we next generated Rosa26 targeted NINJA mice on a B6 genetic background (Fig. S7) . NINJA mice were born at the expected mendelian frequencies and had no distinguishing phenotypes compared to wild-type B6 mice. We first assessed whether there was baseline leaky expression of neoantigens in NINJA mice by looking at the frequency of GFP+ cells in their peripheral blood mononuclear cells (PBMCs; Fig 3A) . As positive controls, we bred NINJA mice to FLPo Tg mice to generate lines that had germline recombination of the neoantigen module and therefore ubiquitous constitutive expression of the NINJA neoantigens (NINJA-F). We also generated NINJA x Cre Tg (NINJA-C) mice, where the regulatory module of NINJA is maintained in the poised state in all cells throughout the body. In NINJA-F mice, all PBMCs were GFP+, while no PBMCs were GFP+ in NINJA mice, suggesting there is no leaky neoantigen expression in NINJA. Interestingly, in NINJA-C mice, >99% of PBLs remained GFP-, although we were able to detect a very small fraction of GFP+ cells (<1%) (Fig 3A; note, this fraction increases with age).
These data suggest that the NINJA allele in mice remains very tightly regulated, without detectable neoantigen expression, except under extreme circumstances where regulatory elements are compromised.
NINJA mice are not tolerant to their neoantigens. To test NINJA mice for central tolerance towards GP33-41 and GP66-77, we bred them to P14 CD8 and SMARTA CD4 TCR Tg mice respectively, and analyzed developing thymocytes. Similar to parental P14 or SMARTA mice (negative control), P14 and SMARTA x NINJA mice had normal development of CD8 and CD4 T cells, while severe defects in the development of CD8 and CD4 T cells became evident in P14 and SMARTA x NINJA-F mice (Fig 3B- 
C).
Consistent with their lack of central tolerance, NINJA mice had robust GP33-41-specific CD8 and GP66-77-specific CD4 T cell responses to acute LCMV infection, which were indistinguishable from the responses developed by control B6 mice, while NINJA-F mice were completely tolerant to the cross-reactive antigens (Fig 3D-E) .
Finally, to confirm that the peripheral environment of NINJA mice did not induce tolerance, we "parked" adoptively transferred 10 6 P14 CD8 T cells in B6, NINJA or NINJA-F mice and infected them with acute LCMV after 14 days. The transferred P14
CD8 T cells were tolerized in the environment of the NINJA-F mice, but instead developed robust responses in both B6 and NINJA mice (Fig 3F) . Together, these data demonstrate that in the absence of neoantigen induction, neoantigen-specific CD8 and CD4 T cells in NINJA mice are not being centrally or peripherally tolerized, as was seen in previous models. To determine if the neoantigen-specific T cells were interacting with neoantigenexpressing cells in the tissues, we transferred dsRed-expressing P14 CD8 T cells into NINJA mice and 24 hr later infected them in the footpad with 10 7 PFU Ad-FLPo. 8 days after infection, we observed dsRed+ P14 T cells localized in the infected footpad in direct proximity to GFP+ skin cells (Fig 4C) . Moreover, P14 T cell accumulation in the infected footpad and acquisition of T cell lytic effector functions (Granzyme B expression) were confirmed by FACS (Fig 4D) . Finally, signs of immunopathology were detected in the infected tissue, as shown by the infiltration of CD3+ cells and thickening of epidermal and dermal layer of the skin as compared to non-infected footpad (Fig 4E) .
Together, these data show that de novo induction of self-neoantigens in the context of an infection with a non-replicating adenoviral vector can trigger a potent effector T cell response in NINJA mice. However, we did not observe increases in the magnitude of the endogenous neoantigen-specific T cell responses in Ad-FLPo:Ad-Cre-infected mice compared to AdFLPo:Ad-GFP-infected mice (Fig S9) , consistent with the hypothesis that, even in the poised state, regulation of NINJA in vivo is maintained tightly.
Endogenous effector T cell responses

Delayed neoantigen induction triggers responses by neoantigen-specific T cells.
To demonstrate the potential of NINJA for applications where dissociating infection and neoantigen induction would be preferable, we next tested a protocol where we infected NINJA x CAG-rtTA3 mice in the footpad with 10 7 PFU Ad-Cre and then waited 14 days before treating them with D/T. Compared with Ad-Cre-infected NINJA x CAG-rtTA3 mice that were treated with D/T at the time of infection, we observed a similar neoantigen-specific endogenous GP33-specific CD8 T cell responses (Fig 5D) ,
suggesting that NINJA mice can be used to trigger neoantigen-specific T cell responses against self-neoantigens under conditions that are not overtly inflammatory.
Discussion
One of the barriers in studies of T cell immunology has been the absence of mouse models with inducible neoantigens that allow for robust endogenous neoantigen-specific CD8 and CD4 T cell responses 3 . Here, we engineered the NINJA mouse model to bypass central and peripheral tolerance by using many levels of regulation to create neoantigens upon induction. This process involved the development of spliced neoantigen-coding genes that require FLPo-regulated inversion 21, 22 . This structure enabled "switch-like" induction of neoantigen expression without leakiness. To allow in vivo control over the switch, we engineered the regulatory module of NINJA to encode FLPo. We validated that the genetic elements in this system were functional both through in vitro analyses, tumor cell line models, and in vivo in NINJA mice. Moreover, we demonstrated that endogenous neoantigen-specific T cells in NINJA mice bypass central and peripheral tolerance mechanisms and respond robustly to local expression of neoantigens by self-tissues. This also confirmed that in NINJA mice, upon in vivo
FLPo-mediated recombination of the neoantigen module, neoantigens are expressed and functionally presented to the components of the immune system. Moreover, we found that we could temporally dissociate the activation of the regulatory module and the neoantigen module, which still resulted in neoantigen-specific CD8 T cell responses two-weeks after the initial infectious event. This would be particularly useful for genetically engineered cancer models (like the KP model) where it is not currently possible to induce neoantigen expression independently from tumor induction.
Together, these data demonstrate that NINJA is a tightly regulated system for inducible neoantigen expression in vivo and is capable of eliciting strong endogenous T cell responses.
The thymus is an organ that is designed to generate central tolerance towards selfantigens. Thymocytes are negatively selected when they encounter low levels of selfantigens expressed by medullary thymic epithelial cells (mTECs) 1, 2 . This alters their development by promoting death or conversion to a regulatory phenotype (like Tregs).
The expression of tissue-restricted antigens is driven by the autoimmune regulator (AIRE), and AIRE deficiency leads to Autoimmune Polyendocrinopathy Syndrome type 1 (APS-1; also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy/dysplasia; APECED) 24 . Yet, it is this high sensitivity to low level expression of self-antigens that has confounded investigators when developing mice with inducible neoantigens. As a consequence, there are many questions regarding peripheral T cell tolerance and autoimmune disease that remain unanswered and NINJA should provide a critical tool by which investigators can begin to address them.
NINJA uses three levels of regulation to control neoantigen induction, but in NINJA-C mice, one of these levels is removed and this results in expression of neoantigens in <1% of cells. This highlights the critical importance of the multiple layers of regulation in NINJA. Interestingly, the pattern of leaky expression in NINJA differs from traditional inducible-models in which a low-level expression is observed from many cells (i.e., all cells in a tissue or the body) 7 . By contrast, in NINJA-C mice, a tiny fraction of cells had full expression of neoantigens, which demonstrates the consequences of leaky expression in a switch-like system. Interestingly, even though only a few cells are neoantigen-positive in NINJA-C mice, they have complete central tolerance towards the neoantigens (data not shown). This efficiency seems to reflect the underlying biology of central tolerance, as only a small fraction (<5%) of mTECs express each tissuerestricted antigen 3 . Critically, we have found that when NINJA mice are bred to mice with Cre expressed under a tissue-specific promoter, the development of tolerance is highly dependent on promoter, as some (like K14-Cre or PDX1-Cre) lead to central tolerance while others (like Alb-Cre) do not (data not shown). Moreover, an additional layer of regulation added by using a CreER transgene instead of Cre (i.e., PDX1-CreER) abrogates these central tolerance phenotypes.
As mentioned above, NINJA is a tool that will enable research in a number of areas in immunology. NINJA was designed to be compatible with many Cre-driven genetically engineered mouse cancer models and will be useful in programming tumors from different cancers to express neoantigens, and thus facilitating studies in cancer immunology. Additionally, NINJA allows for the inducible expression of neoantigens in the absence of inflammation, which will be useful for studies on peripheral tolerance and autoimmune disease. Here, a particularly useful feature of NINJA is the ability to express neoantigens in different cell types or tissue types and determine how targeting these cells causes immune-mediated disease. Along these lines, NINJA may be useful as a model for the study of immune related adverse events (irAEs) after immune checkpoint therapy. NINJA will also be useful in the field of transplantation biology, as one could potentially transplant a syngeneic organ and then express a foreign antigen in that organ after graft acceptance. Finally, the technology in NINJA can be adapted for other scenarios where spatio-temporal control of switch-like induction is desired, such as the induction of suicide genes in specific cell types. Thus, we anticipate that NINJA has many potential applications across a wide range of fields. 
Methods
All
Development and testing of neoantigen module constructs:
Neoantigen Module Version 1 (NM.1): We designed a proof-of-concept construct, in which the GP33-80 region of LCMV was fused to the C-terminus of eGFP (NM.1; Fig   S2A) . To design the DNA sequence (in silico) for our initial construct (see Fig S1B for details), we started with the fusion of eGFP to GP33-80 and then introduced a consensus splice donor (SD) sequence AAG|GTGAGT 5' to the DNA encoding the K amino acid residues highlighted above in GP33-41 and GP66-77 (note, AAG encodes for K). Just 3' to the DNA encoding the A and G amino acid residues in GP33-41 and GP66-77 above (respectively), we inserted a strong splice acceptor (SA) sequence from human adenovirus 5. We also inserted the intronic sequences from the chicken betaactin (cβA) gene (cβA intron or cβAi; contained in the pCAG promoter) between the splice donor and acceptor sequences. This generated a DNA construct that was eGFP:GP33:SD:cβAi:SA:GP34-GP68:SD:cβAi:SA:GP69-80, where the SA:GP34-GP68:SD portion encoded exon 2. We then replaced this exon 2 sequence with its reverse and complement (generating eGFP:GP33:SD:cβAi:SD:GP68- We transiently transfected 293T cells with the NM.1 construct alone or cotransfected the construct with a pcDNA3 plasmid containing FLPo recombinase. Flow cytometric (FACS) analysis showed the construct alone was fluorescent when the neoantigen was in the OFF state (no FLPo), but recombination was induced, we noted a loss of fluorescence intensity in the cells (Fig S2B) . To determine if the protein of the correct size was produced, protein from transfected 293T cells was analyzed by western blotting with an anti-GFP antibody (clone D5.1, Cell Signaling). This corresponded with an increase in protein size from 27 to 32 kDa by western blotting (Fig S2C) . We also confirmed that the correctly spliced products were generated by generating cDNA from 293T cells transfected with the NM.1 construct with and without
FLPo. cDNA was amplified using using PrimeSTAR HS DNA Polymerase (Takara Bio
Inc., cat. R040A) and the primers GFP F AgeI 72 and GP80 R XhoI 64 (Table S1 ). This PCR fragment was cloned into the pCR-Blunt TOPO kit (ThermoFisher Scientific, cat. Fig S3A-B) . In the OFF-state, YFP would also contain amino acids 33 and 69-80 from GP within the loop connecting beta-strands 7 and 8 of YFP (Fig S3B) .
To generate a construct that would become fluorescent after FLPo induction, we next engineered a frame shift such that YFP molecule would require exon 2 to maintain the correct reading frame (i.e., direct splicing of exons 1 and 3 would result in a splicing event that would alter the reading frame; Fig S3C) . This was achieved in silico by adding an A residue into the splice donor sequence at the 3' end of exon 1 and deleting a G from the splice acceptor sequence at the 5' end of exon 2. Next, we engineered the 5' end of exon 3 to contain a TTC -> TTT mutation that was silent when exon 2 spliced to exon 3 (ON state) but created a premature truncation when exon 1 spliced to exon 3.
This would ensure that the OFF state produced only the N-terminal half of YFP.
We synthesized the NM.3 construct with the frameshift, transfected the variant into 293T cells and analyzed their fluorescence by FACS. As a control, we mutated the NM.3 construct to remove A 463 , such that the splicing of exon 1 to exon 3 would occur in frame. As expected, without the frameshift the construct was fluorescent in the OFF state (Fig S3D) . Introduction of the frameshift into the NM.3 construct eliminated the fluorescence of YFP in the OFF state by FACS and resulted in production of only the Nterminus of YFP by Western (Fig S2C) . However, the construct was not fluorescent when co-transfected with plasmid containing FLPo (Fig S3D) , despite the production of a correctly sized protein (Fig S2C) . (Fig S2B-C and S3E ).
We noted that by IF the construct appeared to become less sharp after FLPo and we reasoned this could indicate a protein folding error. Further investigation of the GP33-80 sequence revealed that it contained a hydrophobic region between GP43-GP59, that was strongly predicted to be a transmembrane domain (Fig S3F;  26 ) . To address whether this hydrophobic region was preventing fluorescence, we replaced the sequence with a FLAG tag sequence, which eliminated the transmembrane domain (Fig   S3F; NM.6). The resulting construct was indeed fluorescent in the ON state (Fig S2D) .
Thus, we had developed an inversion-mediated fluorescent neoantigen that was regulated by FLPo.
Version 7 (NM.7): Neoantigen non-immunogenic in the OFF state. In the unlikely event there was transcription of Exon 2 (in the opposite direction), there was a concern that a peptide could be produced that could mimic GP33-41 and cause tolerance. Note, there is an upstream SV40 poly A sequence in the inverted direction to minimize this risk. We analyzed the potential peptide products from this construct and realized that, due to the structure of the splice acceptor, the DNA sequence encodes GP34-41 and that the amino acid proceeding this was encoded by nCA, which could encode an Ala, Ser, Thr, or Pro residue (Fig S4A) . We calculated the predicted binding of each peptide (GP34-41 or GP33-41 with K33A, K33S, K33T, or K33P mutations, Fig S4B) and found that K33A, K33S, and K33T bound as strongly or more strongly to H2-D b as the wt GP33-41 peptide. We also confirmed that K33A, K33S, and K33T bind to H2-D b using RMA-S cells, and that K33A and K33S could activate GP33-specific P14 TCR Tg CD8 T cells (Fig S4C and data not shown) . By contrast GP34-41 and K33P did not bind to H2-D b or stimulate T cell activation, although GP34-41 did bind to H2-K b as previously reported 27 .
We engineered the splice acceptor in Exon 2 so that it encoded K33P in the OFF state and we added the amino acids GP42-43 (Fig S2A -NM.7) , which increase the affinity of GP33-41 for D b to a more physiologic level 27 .
Development and testing of regulatory module constructs:
Development of FLPoER 251 : We generated a FLPoER fusion by fusing amino acids 282-596 of the human estrogen receptor (hER) containing the T2 mutations (G400V, M543A, and L544A; 28 ) to the C-terminus of FLPo but identified that this had relatively weak activity in reporter cells upon 4-hydroxytamoxifen treatment (4-OHT; Fig S5A) .
Previous work in yeast suggested that fusing a longer portion of ER (251-596) to FLPe recombinase can increase activity, although this was not tested in mammalian cells 21 .
We synthesized this version (henceforth called FLPoER 251 ) and verified that it was more responsive to 4-OHT treatment and that its activity was not increased by estrogen (E2) treatment (Fig S5A) . FLPoER 251 was leakier than FLPoER, but because it was one of three elements in the regulatory module, we chose to trade-off increased leakiness for increased responsiveness to 4-OHT and proceeded with FLPoER 251 .
Creating spliced FLPoER 251 for the regulatory module: Next, we assembled a Rosa26 targeting vector, which consisted of pTRE:Lox-STOP-Lox (LSL):FLPoER 251 (Fig S5B) , 2x CGG insulator, and the neoantigen module. Upon assembly, however, we discovered that the neoantigen module in this construct was being recombined by FLPo activity in E coli (Fig S5C; note neither (Fig 1A) .
To generate the inversion-inducible FLPoER 251 construct, we first split FLPo into Nand C-terminal halves. Based on its crystal structure, we decided to split FLPo between a-helices I and J, which would split the catalytic residues across two exons. We introduced splicing sites as before, taking advantage of K285 and D286 and engineering an intron with SA and SD sequences from intron 2 of mouse p53. Here, exon 2 was inverted relative to exon 1 and placed between non-compatible lox sites (responsive to Cre-recombinase; 30 ). Downstream of exon 2, we included a poly A sequence from herpes simplex virus (HSV), which is predicted to terminate transcription in both the 5' -> 3' and 3' -> 5' directions. Thus, in the OFF state, the HSV poly A was oriented in such a manner that it should terminate the RNA transcript for N-terminal For integration into the larger construct, we reoriented the regulatory module such that it would run 3' to 5' relative to the neoantigen module. This meant that the pTREtight promoter would be next to the 2x CGG insulator and the Rosa promoter (outside of the construct) would be transcribed in the opposite direction of the regulatory module.
To prevent issues with transcription in both directions and to allow for selection of clones after integration, we inserted a cassette for puromycin resistance in the 5' most end of the regulatory module (Fig S6) . This consisted of the PGK promoter, the puromycin resistance gene and the HSV poly A sequence. In the OFF configuration, this element would provide puromycin resistance and also terminate the endogenous transcript from the Rosa 26 promoter. Moreover, after Cre-mediated recombination in the regulatory module, this puro resistance cassette would be genetically deleted.
Assembly of the NINJA targeting construct:
The regulatory and neoantigen modules were inserted into the pzDonor Rosa26 targeting construct separated by the 2xCGG insulator to minimize the impact of the CMV enhancer on the pTRE-tight promoter. Moreover, a pgk-puromycin resistance cassette was inserted into the regulatory module in such a way that the HSV poly A sequence was predicted to terminate transcription downstream of the Rosa26 promoter.
However, the puromycin resistance cassette is lost following Cre-mediated recombination, providing an assay for recombination at this allele. 
Lymphocyte isolation from spleen and LN
Organs were processed as described previously 32 .
To purify CD8 + T cells from the spleen of TCR transgenic P14 mice, the EasySep Kit (StemCell Technologies, cat. 18000) was used according to manufacturer's instructions. Recipient animals were euthanized 7 days after BMDC transplant to collect spleen and the draining LN (popliteal). Organs were processed as described in 32 and samples were stained with antibodies specific for Thy1.1 (clone OX-7, BioLegend), Thy1.2 (clone 30-H12, BioLegend), CD4 (clone GK1.5, BioLegend) and CD8 (clone 53-6.7, BioLegend).
DC2.4 proliferation and killing assay
Cells were then analysed on a BD LSRII flow cytometer (BD Biosciences).
Creation of the NINJA transgenic lung tumor cell line.
A B6 cell line derived from an Ad-CRE-infected Kras G12D p53 fl/fl mouse was cotransfected with the NINJA targeting construct and RNA encoding a zinc-finger nuclease targeting the Rosa26 locus (Millipore Sigma) using Amaxa nucleofector (Lonza). We generated a KP-NINJA line and verified that the NINJA construct was targeted to the Rosa26 locus. Single-cell clones were selected based on Puro resistance and screened for incorporation of the NINJA targeting vector by PCR. The C4 clone was selected for further study. rtTA was stably introduced into C4 cells via a dual promoter retrovirus expressing rtTA and a blasticidin resistance cassette (C4A3). A blasticidin-resistant single cell clone (C4A3D6) was selected and infected with Ad-CRE to mediate recombination of the regulatory module. Activation of the neoantigen module was achieved by incubating C4A3D6 cells in vitro with doxycycline (1ug/ml) and 4-hydroxytamoxifen (1ug/ml) for 72 hours.
Generation of the NINJA mouse
Targeting was performed by the Swanson Biotechnology Center Preclinical Modeling facility of MIT. Briefly, NINJA mice were generated by transfecting the PvuI-HF linearized NINJA targeting construct into B6 ES cells (JM8) along with mRNA encoding
ZFNs for the Rosa26 locus (Millipore Sigma). We screened clones for proper targeting by southern blotting and identified one correctly targeted clone (Fig S7) . We injected these targeted ES cells into B6 blastocysts and selected a high percentage chimera (>80%) for breeding to a B6 female. This breeding resulted in germline transmission in two pups that were used to produce the NINJA mouse line.
NINJA-F and NINJA-C mice were generated by crossing NINJA mice to FLPe or Cre deleter mice (JAX, stock # 003946) and (JAX, stock # 006054) respectively and then crossing FLPe+ or Cre+ F1 mice to B6 mice and screening the progeny for FLPe-or
Cre-driven recombination at the NINJA locus. Mice were bred to homozygosity and maintained as independent strains. NINJA x CAG-rtTA3 were generated by crossing NINJA mice to CAG-rtTA3 mice (JAX, stock # 016532).
Genotyping of NINJA, NINJA x CAG-rtTA3, NINJA-C, and NINJA-F mice
Mouse tail DNA was amplified using KAPA Taq PCR Kit (Takara Bio, cat. R040A) and primers Rosa26 WT F, Rosa26 WT R, and Rosa26 Ninja R (Table S1 ). Expected bands were 378bp for WT allele and 280 bp for NINJA allele. For CAG-rtTA3 genotyping, primers CAGrtTA common F, CAGrtTA WT R and CAGrtTA Transgene R (Table S1) were used and expected bands were 360bp for WT allele and 330bp for Transgene.
For NINJA-C, Rosa26 WT F, Rosa26 NINJA R, and Rosa26 Ninja-C R primers (Table   S1 ) were used for expected bands of 280 bp for unrecombined NINJA allele or 694 bp for NINJA allele with recombination in RM. For NINJA-F mice, Rosa26 Ninja-F F and Rosa26 Ninja-F R primers (Table S1 ) were used for expected bands of 784 bp for unrecombined NINJA or 442 bp for NINJA allele with recombination in RM.
Southern Blot
DNA from ES cell clones was digested with BamHI or EcoRV overnight and then was run on a 0.7% TAE gel overnight at 25-35 V. Gel was HCl depurinated, NaOH denatured, and neutralized using standard protocols and transferred passively to Hybond XL membrane via wicking method. Blot was UV-crosslinked using a Stratalinker (Stratagene) and was probed using dCTP-32P labeled probes made using the PrimeIT II kit (Agilent, cat. 300385) and Roche Quick Spin Columns (TE, cat. 11532015001).
The template for the southern probe was made from a 817 bp fragment amplified from B6 genomic DNA with primers Rosa26 southern probe F and R (Table S1 , 33 ).
P14/SMARTA crosses
NINJA, NINJA-C and NINJA-F mice were crossed with either GP33-43-specific TCR transgenic P14 mice or with GP66-77-specific TCR transgenic SMARTA mice.
Developing T cells were harvested from the thymus of 6-8 weeks old litters and analysed by flow cytometry on a BD Biosciences LSRII analyser after staining with antibodies specific for Thy1.2 (clone 30-H12, BioLegend), Thy1.1 (clone OX-7, BioLegend), CD8 (clone 53-6.7, BioLegend), CD4 (clone GK1.5, BioLegend).
Analysis of PBMCs for NINJA expression
6-10 weeks old NINJA, NINJA-C, NINJA-F and wild-type B6 mice were bled retroorbitally using heparinized glass capillaries (Fisher Scientific, cat. 22362566) to collect 50-100uL of blood into 0.04% Citrate Buffer. Red blood cells were lysed using 1x RBC Lysis Buffer (eBioscience, cat. 00-4333-57) and the remaining PBMCs were analysed by flow cytometry on a BD Biosciences LSRII analyser for detection of GFP expression.
LCMV-Armstrong infections
7-10 weeks old NINJA, NINJA-F or age-matched wild-type B6 mice were infected intraperitoneally with 2 * 10 5 PFU/mouse of LCMV-Armstrong. For P14 tolerance induction assay, Thy1.1 + /1.1 + 10 6 P14 cells were adoptively transferred through retroorbital I.V. injection into recipient mice two weeks before infection with LCMVArmstrong. Mice were euthanized 8 days after infection to collect and process spleens as described in 32 .
In vitro antigen-specific restimulation and flow cytometry
For antigen-specific restimulation, 1 * 10 6 splenocytes were cultured for 6hr at 37°C in 5% CO 2 in complete RPMI-1640 (10% HI-FBS, 55μM beta-mercaptoethanol, 1x 25608-930) on dry ice for freezing.
For IHC, tissues were fixed in a 1x formaldehyde solution in PBS (Millipore-Sigma) and then embedded in paraffin and sectioned by the Yale Pathology Core Facility. All tissues were sectioned and stained as previously described 31 . Table S1 . 
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